Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed Jun 3, 2016
Insider Transaction Report
Form 4
DOUMANI ROY
Director
Transactions
- Award
Common Stock
2016-06-01+1,950→ 141,017 total - Award
Director Stock Option (Right to Buy)
2016-06-01+7,000→ 7,000 totalExercise: $50.87Exp: 2026-05-31→ Common Stock (7,000 underlying)
Holdings
- 31,865(indirect: By Spouse)
Common Stock
Footnotes (1)
- [F1]The stock option shall vest in 24 successive equal monthly installments following the date of grant.